Navigation Links
Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference
Date:1/4/2012

ttp://www.generex.com/">www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded a
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 You,re visiting the dentist for ... when he or she says you need a root ... you may have several questions and feel apprehensive about ... know it,s nothing to worry about. The Pennsylvania Dental ... alleviate any anxiety the public may have surrounding this ...
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "Micro Market Monitor: North ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is progressing steadily, which has resulted in fueling ... market. The main purpose of these dermatology devices ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... DIEGO, Aug. 8, 2011 CareFusion Corp. (NYSE: ... results for the quarter and fiscal year ended June 30, ... Prevention businesses, gross margin expansion and the benefit of strong ... earnings for the quarter and for the year," said Kieran ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... June 30, 2011. Quarterly Financial Highlights ... revenue for NUEDEXTA® of $2.2 million Cash, cash equivalents, and ... "I am thrilled with the progress we are making ...
Cached Medicine Technology:CareFusion Reports Fourth Quarter and Fiscal 2011 Results 2CareFusion Reports Fourth Quarter and Fiscal 2011 Results 3CareFusion Reports Fourth Quarter and Fiscal 2011 Results 4CareFusion Reports Fourth Quarter and Fiscal 2011 Results 5CareFusion Reports Fourth Quarter and Fiscal 2011 Results 6CareFusion Reports Fourth Quarter and Fiscal 2011 Results 7CareFusion Reports Fourth Quarter and Fiscal 2011 Results 8CareFusion Reports Fourth Quarter and Fiscal 2011 Results 9CareFusion Reports Fourth Quarter and Fiscal 2011 Results 10CareFusion Reports Fourth Quarter and Fiscal 2011 Results 11CareFusion Reports Fourth Quarter and Fiscal 2011 Results 12CareFusion Reports Fourth Quarter and Fiscal 2011 Results 13CareFusion Reports Fourth Quarter and Fiscal 2011 Results 14CareFusion Reports Fourth Quarter and Fiscal 2011 Results 15Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 2Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 3Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 4Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 5Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 6Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 7Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 8
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... York, New York (PRWEB) December 21, 2014 ... ) and other product liability claims involving a ... incretin mimetics continue to move forward in a ... Court, Southern District of California, Bernstein Liebhard LLP ... the Court has established a data cut-off date ...
(Date:12/21/2014)... The number of Mirena lawsuits ( ... underway in New Jersey, Bernstein Liebhard LLP reports. , ... involving the birth control IUD have now been filed ... by women who allege spontaneous migration of the device, ... and other complications they were inadequately warned about by ...
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... Theme and plugin developers from ... for Final Cut Pro X entitled ProMotion. , “ProMotion ... with absolute ease.” Said Christiana Austin, CEO of Pixel ... to easily animate their media inside FCPX.” , Pixel ... to animate pictures, videos, logos, and more with absolute ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... release is available in Spanish . , What ... a disease? What affects the ideas and beliefs that patients ... Granada have developed a test for measuring and assessing ... enable the development of clinical psychological treatments much more efficient ...
... HealthDay Reporter , WEDNESDAY, Oct. 20 (HealthDay News) ... for new warnings on the labels of widely used hormonal ... risk of heart disease and diabetes in the men who ... it was reviewing the prostate cancer drugs known as gonadotropin-releasing ...
... Calif.) A study of the options for reducing ... treated for precancerous cervical lesions found that an annual ... Joy Melnikow, professor in the Department of Family ... strategies for the 500,000 American women diagnosed and treated ...
... Computed tomography colonography (CTC) otherwise known as virtual ... optimal colonoscopy is limited, according to a study in ... ( www.ajronline.org ). The study was performed ... and Tuba City Regional Health Care Center in Tuba ...
... Oct. 20 -- Scientists and engineers from around the world ... N.Y. next week to discuss some of the latest breakthroughs ... the development of new materials, and medicine. Journalists are ... the 94th annual meeting of the Optical Society (OSA), which ...
... Oct. 20 (HealthDay News) -- Fatalism, a belief that life,s ... have some of the lowest cancer screening rates in the ... more likely than white women to believe that cancer is ... with cancer, the researchers found. Karla Espinosa de los ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 3Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Fatalistic Attitudes May Keep Hispanic Women From Cancer Tests 2
... HEp-2000 ANA uses a patented HEp-2 ... to increase the sensitivity to SS-A/Ro autoantibodies, ... Several independent studies have been published worldwide ... increased sensitivity to SS-A/Ro autoantibodies when used ...
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... Indirect Fluorescence Assay (IFA) for IgG ... for the qualitative and semi-quantitative detection ... in human serum. Detection of ANA ... an aid in the diagnosis of ...
Medicine Products: